Working with the body to fight cancer, not against it
Allowing lower, better-tolerated doses of chemotherapy and radiotherapy
A disruptive technology to transform the management of cancer
Aiming to move cancer treatments from extending lives to saving lives

Our Science

Veyonda is a first-in-class activator of the innate immune system. This is the system that scientists increasingly are beginning to see must be activated if a cancer is to have any chance of being permanently eradicated.

Pipeline and Clinical Trials

Establishing Veyonda as an essential adjunct to radiotherapy in the treatment of prostate cancer and discharging portfolio risk by studying Veyonda in combination with radiotherapy and non-radio therapy treatments.

Features & Upcoming Events

Wednesday November 20th at 2pm
Noxopharm 2019 Annual General Meeting
Museum of Sydney cnr Phillip & Bridge Sts Sydney
To register for webcast and AGM questions: Register here.
November 12-14, 2019
COSA Annual Meeting - Adelaide, SA
November 20, 2019
Noxopharm 2019 AGM - Sydney, NSW

About Cancer